AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Anthem Biosciences gains 30% from its IPO price on Mumbai debut
ByAinvest
Monday, Jul 21, 2025 12:32 am ET1min read
Anthem Biosciences gains 30% from its IPO price on Mumbai debut
Anthem Biosciences, a leading contract research and manufacturing organization (CRDMO) based in Bengaluru, made its market debut today, July 21, with a significant gain from its initial public offering (IPO) price. The stock listed at Rs 723, representing a 27% premium over the IPO price of Rs 570, according to the grey market premium (GMP) [1].The IPO, which was priced between Rs 540 and Rs 570 per share, was highly subscribed, with an overall subscription of 67.4 times. Qualified Institutional Buyers (QIBs) led the charge, subscribing 192.8 times their allotted quota, while Non-Institutional Investors (NIIs) followed with a 44.7 times bid, and the retail category was booked nearly 6 times [2].
Anthem Biosciences operates across the drug development lifecycle, providing end-to-end services for both small molecules and biologics. The company reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore for the fiscal year ending March 2025 [3].
The strong demand for Anthem Biosciences' shares is reflected in the GMP of Rs 169, indicating an estimated listing price of around Rs 739 per share, which is a 29.65% potential gain over the issue’s upper price band of Rs 570 per share [1].
The company's robust financial performance, high-margin model, and leadership position in the CRDMO space have drawn significant investor interest. However, the steep valuation and high premium listing will require close monitoring of its post-listing performance and growth trajectory [3].
References:
[1] https://www.financialexpress.com/market/ipo-news-anthem-bioscience-ipo-listing-today-big-debut-or-flat-start-heres-what-gmp-indicates-3920947/
[2] https://www.business-standard.com/markets/capital-market-news/anthem-biosciences-ipo-ends-with-63-86x-subscription-125071700340_1.html
[3] https://m.economictimes.com/markets/stocks/news/anthem-biosciences-ipo-listing-today-check-gmp-ahead-of-debut/articleshow/122804458.cms
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet